Importance of adherence to BCR-ABL tyrosine-kinase inhibitors in the treatment of chronic myeloid leukemia
| Autor: | Maria Helena Morgani de Almeida, Dulce Couto, Laura Fogliatto |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2014 |
| Předmět: |
Oncology
medicine.medical_specialty BCR-ABL positive business.industry Poor compliance lcsh:RC633-647.5 Treatment outcome Leukemia chronic myeloid Myeloid leukemia Patient compliance Hematology lcsh:Diseases of the blood and blood-forming organs Therapeutics Review article Internal medicine hemic and lymphatic diseases Immunology medicine Adverse effect business Bcr-Abl Tyrosine Kinase Tyrosine kinase |
| Zdroj: | Revista Brasileira de Hematologia e Hemoterapia v.36 n.1 2014 Revista brasileira de hematologia e hemoterapia Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC) instacron:ABHHTC Revista Brasileira de Hematologia e Hemoterapia, Vol 36, Iss 1, Pp 54-59 (2014) Revista Brasileira de Hematologia e Hemoterapia Revista Brasileira de Hematologia e Hemoterapia, Volume: 36, Issue: 1, Pages: 54-59, Published: JAN 2014 |
| Popis: | Treatment of chronic myeloid leukemia with BCR-ABL tyrosine kinase inhibitors requires full adherence in order to maximize the likelihood of achieving optimal responses, and to minimize healthcare costs. In this article, we review some of the methods available for assessing compliance, the main consequences of nonadherence on treatment outcomes, major factors commonly associated with poor compliance, a few successful measures for improving adherence and the most accepted recommendations for proactively managing adverse events.© 2014 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier Editora Ltda. All rights reserved. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|